LATEST ARTICLES

Invitrocue Leads Market With Personalised Oncology Solutions

Invitrocue Ltd (ASX:IVQ) chief executive officer Steven Fang speaks to Proactive Investors about the oncology-focused company's development of cancer treatments by testing specific drugs on laboratory-controlled micro-tumours. "We've been able to take some of these really innovative, disruptive technologies and apply it to the space of being able to create these micro-tumours," says Fang. He continues,...

Life in the Time of Coronavirus

/* custom css */ .td_uid_1_5f08d90f8178c_rand { min-height: 0; } /* custom css */ .td_uid_2_5f08d90f81973_rand { vertical-align: baseline; } REGISTER NOW jQuery(window).load(function () { jQuery('body').find('#td_uid_1_5f08d90f81785 .td-element-style').each(function (index, element) { jQuery(element).css('opacity', 1); return; }); }); jQuery(window).ready(function () { // We need timeout because the content must be rendered and interpreted on client setTimeout(function () { var $content = jQuery('body').find('#tdc-live-iframe'), refWindow...

Study pinpoints brain cells that trigger sugar cravings and consumption

Credit: Matthew Potthoff, University of Iowa Carver College of Medicine New research has identified the specific brain cells that control how much sugar you eat and how much you crave sweet tasting food. Most people enjoy a sweet treat every now and then. But an unchecked “sweet tooth” can lead to overconsumption of...

Life Sciences Fund Launches with €76M to Invest in Nordic Biotech

Stockholm and Copenhagen-based Eir Ventures has announced the closure of its first fund at €76M, which will be used to invest in biotechs and other life science companies, with a focus on the Nordics. The fund is backed by Saminvest, a venture capital company founded by the Swedish Government; Vækstfonden, the Danish state’s investment fund; Novo Holdings; and the European...

VarmX bags €32m in Series B round – European Biotechnology News

Leiden-based coagulant developer VarmX NV has closed a €32m Series B financing to push the Phase II development of VMX-C001, a venom-based modified recombinant Factor X. New investors LSP, Ysios Capital, INKEF Capital and Lundbeckfonden Ventures joined the financing round, with the contribution of existing investors BioGeneration Ventures and InnovationQuarter. VarmX develops oral drugs for the treatment and prevention of...

Salmonella biofilm protein can cause autoimmune responses, arthritis in animals

Scientists from the Vaccine and Infectious Disease Organization-International Vaccine Centre (VIDO-InterVac) at the University of Saskatchewan (USask) and Temple University (Philadelphia, U.S.) have demonstrated that a Salmonella biofilm protein can cause autoimmune responses and arthritis in animals. Salmonella was previously thought to only form biofilms in the environment, such as on food processing surfaces. Biofilms are dense collections of bacteria...

Volunteers can now register for coronavirus disease vaccine trials

As the world grapples with the coronavirus pandemic, many pharmaceutical companies, and research organizations are racing to develop an effective vaccine against the novel coronavirus, called the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Human trials are now being conducted to determine candidate vaccine efficacy and safety. Currently, there are 21 candidate vaccines in clinical evaluation,  and 139 candidate vaccines...

Genexine and NeoImmuneTech (NIT) – GX-I7 [also called NT-17 or Hyleukin-7™ (rhIL-7-hyFc)]

Candidate: GX-I7, also known as NT-17 or Hyleukin-7 (rhIL-7-hyFc) Type: Homeostatic T cell growth factor composed of a covalently linked homodimer of engineered Interleukin-7 (IL-7) molecule, biologically fused with the proprietary long-acting platform – hyFc. GX-I7 is designed to amplify and enhance the number of T cells that occupy most of the lymphocytes, reinvigorating persistent T cell immunity by increasing...

Trust me if you can

Why stakeholders in the ‘wind energy vs biological conservation’ conflict have low mutual trust and how to increase it Credit: Christian Voigt, IZW Wind energy is considered to be one of the most promising forms of renewable energy. Yet, each year, wind turbines are responsible for the death of hundreds of thousands of...

€18M to Fund First-in-Class Systemic Sclerosis Drug

One of the largest biotech placements in the Nordic countries this year will accelerate the development of a first-in-class drug for chronic inflammation conditions such as systemic sclerosis that lacks the cardiovascular risks of current medications such as aspirin. Swedish biotech Gesynta Pharma raised €18.2M (SEK 190M) in a placement supported by returning investor Industrifonden as well as European life...

China Pursuing ‘Aggressive’ Biotechnology Strategy – National Defense Magazine

iStock illustration As rapid innovation in computer sciences helps bolster advances in biotechnologies, China is edging forward as a world leader in the biotech sector, one expert said. “Biotechnologies, including synthetic biology, are going to be foundational to the 21st century economy and they’re also going to be a critical arena for global competition in the geopolitical realm,” said Tara O’Toole,...